Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HBM9161 in generalized myasthenia gravis (China, Phase III)
CTR20212099Phase 3Completed
- Sponsor
- Harbour BioMed
- Start
- Sep 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in myasthenia gravis (MG) comparing HBM9161 with Placebo (2 arms). Primary endpoint: Proportion of antibody-positive patients with sustained improvement in MG-ADL score versus baseline (each visit). Started Sep 2021; status: completed.
02
Drugs
batoclimab
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on CTR20212099.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212099.